Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues.
about
TEL is a sequence-specific transcriptional repressorTargeting of the visna virus tat protein to AP-1 sites: interactions with the bZIP domains of fos and jun in vitro and in vivo.Mutual inhibition between Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus lytic replication initiators in dually-infected primary effusion lymphomaMethylation-dependent binding of the epstein-barr virus BZLF1 protein to viral promotersActivation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation.The Epstein-Barr virus lytic transactivator Zta interacts with the helicase-primase replication proteins.The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.Genetic dissection of cell growth arrest functions mediated by the Epstein-Barr virus lytic gene product, ZtaSumoylation of the Epstein-Barr virus BZLF1 protein inhibits its transcriptional activity and is regulated by the virus-encoded protein kinase.BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186.The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16.The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteinsCCAAT/enhancer binding protein alpha interacts with ZTA and mediates ZTA-induced p21(CIP-1) accumulation and G(1) cell cycle arrest during the Epstein-Barr virus lytic cycle.Mutational analysis reveals a role for the C terminus of the proteasome subunit Rpt4p in spindle pole body duplication in Saccharomyces cerevisiae.Physical and functional interaction of the Epstein-Barr virus BZLF1 transactivator with the retinoic acid receptors RAR alpha and RXR alpha.T cell epitope clustering in the highly immunogenic BZLF1 antigen of Epstein-Barr virus.Amino acids in the basic domain of Epstein-Barr virus ZEBRA protein play distinct roles in DNA binding, activation of early lytic gene expression, and promotion of viral DNA replication.The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activityPhosphoacceptor site S173 in the regulatory domain of Epstein-Barr Virus ZEBRA protein is required for lytic DNA replication but not for activation of viral early genes.Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: activation of transforming growth factor beta igh3 (TGF-beta igh3) and TGF-beta 1The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitorsCharacterization of the ZI domains in the Epstein-Barr virus BZLF1 gene promoter: role in phorbol ester induction.Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replicationA replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.Changing Epstein-Barr viral ZEBRA protein into a more powerful activator enhances its capacity to disrupt latencyViral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylationThe bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa BDNA-binding-defective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificitiesThe Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular Sp1 transcription factorCharacterization of the Epstein-Barr virus BZLF1 protein transactivation domain.ZEBRA and a Fos-GCN4 chimeric protein differ in their DNA-binding specificities for sites in the Epstein-Barr virus BZLF1 promoter.Efficient transcription of the Epstein-Barr virus immediate-early BZLF1 and BRLF1 genes requires protein synthesis.Latency of Epstein-Barr virus is disrupted by gain-of-function mutant cellular AP-1 proteins that preferentially bind methylated DNA.Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism.CCAAT/enhancer binding protein alpha binds to the Epstein-Barr virus (EBV) ZTA protein through oligomeric interactions and contributes to cooperative transcriptional activation of the ZTA promoter through direct binding to the ZII and ZIIIB motifs dReplication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays.Novel autoregulatory function of hepatitis B virus M protein on surface gene expression.Amino-acid change in the Epstein-Barr-virus ZEBRA protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa.Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.
P2860
Q22010632-1EF93141-33EA-4CEF-A1D1-988E6266C374Q24516921-614A0D0B-07F1-4432-935E-BC9176B4B249Q28472086-F7F89BA0-9726-4B14-8055-D450BCC1EF91Q33422971-1C25D621-0DBB-48DC-8D8F-9D2AE0654405Q33784820-4257F8B0-3084-4CDF-8495-94C1005B9167Q33785198-206E5EC5-271A-48F8-AF90-A12F63B9C548Q33817111-2BC4D661-22AD-4E8B-885B-B688302CF6CAQ33822549-15C6DC3F-1169-402B-8F3B-162D9FEDA2EBQ33826641-C5E8E8B3-01C0-4124-9DA2-2A614454C809Q33843046-DFD61B2F-05B1-46B3-91BC-35D35189C050Q33936163-6743A31D-CBB6-4690-A01D-981AE5B83C34Q34291099-02B14E2D-99B1-45F2-A8E1-34C77184C260Q34465924-6638346B-C6EB-4F2A-B662-43CA5AA8DE18Q34616090-BDA8B1C7-BBE8-4AF7-9007-EF1AC9424367Q34751026-B002FDBB-F60E-4F45-82C1-F797C93D0F03Q34992684-D9B3E66E-70B2-4340-ACBE-73DDAA51EF79Q35024349-DAD2E3D5-F80C-4A5C-A318-E5FBB3D58EC4Q35603820-81D7553B-5F08-4BE8-99C2-561A3EEB1020Q35785209-E206CA03-6519-4E4E-A20C-9F8A3DA4AB45Q35841284-2AFB574C-51ED-435E-BBA6-06B52AA0CC99Q35851139-20340C2C-449F-4168-A6FB-BE59E13B5A08Q35861789-443487C5-E2FB-41C5-AA61-AE7FE5EFBFCBQ35865903-762127B5-F84A-4C9F-8684-F75CB28D42A3Q35873179-E269594B-DF9F-4EB6-9473-74F9740C7FE3Q36298743-50AB1F6D-397B-4C29-8CD7-F11B9C6E534AQ36559479-4E45C4C1-F5C0-4548-8768-AE5C62AC27C7Q36634417-3C025D02-85A7-421F-A9BF-205907417A47Q36648227-DCDD9302-240C-43B2-97B4-91C596E8E486Q36652041-417EA157-668B-4C3E-A6EB-998106386E15Q36687270-DE2C3A19-366E-4A91-83FC-3D85D7E2E8F1Q36690559-0BA68073-4100-46E7-B06E-9C7CD1119BEEQ36797008-AEC7B9E9-9F58-45DC-ADD7-9D21206D2834Q36829168-F9A7764F-A6CA-48B7-9D57-B64D58C37C9EQ36855331-167F69A6-FE1E-4C5F-8D6D-2CC39D9DE890Q37389141-76DCA658-1442-460A-AFA4-F539E3679503Q37422745-6F7635CE-681D-422F-A161-95D8DD36FC6BQ38296033-867E9381-FADD-4749-BE44-AFE1CEFD3E59Q38326159-78D32668-2F88-4EE4-A1FF-BD02A7363C3EQ39034599-9C3E3B9A-3483-4AF6-9985-7885FD5E2E30Q39296826-1E871F96-8333-481A-B123-02414F4D6363
P2860
Evidence for coiled-coil dimer formation by an Epstein-Barr virus transactivator that lacks a heptad repeat of leucine residues.
description
1990 nî lūn-bûn
@nan
1990 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@ast
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@en
type
label
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@ast
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@en
prefLabel
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@ast
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@en
P2860
P356
P1476
Evidence for coiled-coil dimer ...... ad repeat of leucine residues.
@en
P2093
E Flemington
P2860
P304
P356
10.1073/PNAS.87.23.9459
P407
P577
1990-12-01T00:00:00Z